108 related articles for article (PubMed ID: 20800650)
1. Overexpression of CD133 promotes the phosphorylation of Erk in U87MG human glioblastoma cells.
Dong L; Qi N; Ge RM; Cao CL; Lan F; Shen L
Neurosci Lett; 2010 Nov; 484(3):210-4. PubMed ID: 20800650
[TBL] [Abstract][Full Text] [Related]
2. Analysis of an alternative human CD133 promoter reveals the implication of Ras/ERK pathway in tumor stem-like hallmarks.
Tabu K; Kimura T; Sasai K; Wang L; Bizen N; Nishihara H; Taga T; Tanaka S
Mol Cancer; 2010 Feb; 9():39. PubMed ID: 20167130
[TBL] [Abstract][Full Text] [Related]
3. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway.
Ma S; Lee TK; Zheng BJ; Chan KW; Guan XY
Oncogene; 2008 Mar; 27(12):1749-58. PubMed ID: 17891174
[TBL] [Abstract][Full Text] [Related]
4. Modulation of invasive properties of CD133+ glioblastoma stem cells: a role for MT1-MMP in bioactive lysophospholipid signaling.
Annabi B; Lachambre MP; Plouffe K; Sartelet H; Béliveau R
Mol Carcinog; 2009 Oct; 48(10):910-9. PubMed ID: 19326372
[TBL] [Abstract][Full Text] [Related]
5. CD133(+) liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling.
Tang KH; Ma S; Lee TK; Chan YP; Kwan PS; Tong CM; Ng IO; Man K; To KF; Lai PB; Lo CM; Guan XY; Chan KW
Hepatology; 2012 Mar; 55(3):807-20. PubMed ID: 21994122
[TBL] [Abstract][Full Text] [Related]
6. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles.
Beier D; Hau P; Proescholdt M; Lohmeier A; Wischhusen J; Oefner PJ; Aigner L; Brawanski A; Bogdahn U; Beier CP
Cancer Res; 2007 May; 67(9):4010-5. PubMed ID: 17483311
[TBL] [Abstract][Full Text] [Related]
7. Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells.
Suetsugu A; Nagaki M; Aoki H; Motohashi T; Kunisada T; Moriwaki H
Biochem Biophys Res Commun; 2006 Dec; 351(4):820-4. PubMed ID: 17097610
[TBL] [Abstract][Full Text] [Related]
8. Expression and regulation of AC133 and CD133 in glioblastoma.
Campos B; Zeng L; Daotrong PH; Eckstein V; Unterberg A; Mairbäurl H; Herold-Mende C
Glia; 2011 Dec; 59(12):1974-86. PubMed ID: 21901757
[TBL] [Abstract][Full Text] [Related]
9. Coexpression analysis of CD133 and CD44 identifies proneural and mesenchymal subtypes of glioblastoma multiforme.
Brown DV; Daniel PM; D'Abaco GM; Gogos A; Ng W; Morokoff AP; Mantamadiotis T
Oncotarget; 2015 Mar; 6(8):6267-80. PubMed ID: 25749043
[TBL] [Abstract][Full Text] [Related]
10. Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors.
Yi JM; Tsai HC; Glöckner SC; Lin S; Ohm JE; Easwaran H; James CD; Costello JF; Riggins G; Eberhart CG; Laterra J; Vescovi AL; Ahuja N; Herman JG; Schuebel KE; Baylin SB
Cancer Res; 2008 Oct; 68(19):8094-103. PubMed ID: 18829568
[TBL] [Abstract][Full Text] [Related]
11. miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1.
Ma S; Tang KH; Chan YP; Lee TK; Kwan PS; Castilho A; Ng I; Man K; Wong N; To KF; Zheng BJ; Lai PB; Lo CM; Chan KW; Guan XY
Cell Stem Cell; 2010 Dec; 7(6):694-707. PubMed ID: 21112564
[TBL] [Abstract][Full Text] [Related]
12. CD133+ liver cancer stem cells resist interferon-gamma-induced autophagy.
Li J; Chen JN; Zeng TT; He F; Chen SP; Ma S; Bi J; Zhu XF; Guan XY
BMC Cancer; 2016 Jan; 16():15. PubMed ID: 26758620
[TBL] [Abstract][Full Text] [Related]
13. Effect of CD133/prominin-1 antisense oligodeoxynucleotide on in vitro growth characteristics of Huh-7 human hepatocarcinoma cells and U251 human glioma cells.
Yao J; Zhang T; Ren J; Yu M; Wu G
Oncol Rep; 2009 Oct; 22(4):781-7. PubMed ID: 19724856
[TBL] [Abstract][Full Text] [Related]
14. Glioma cell populations grouped by different cell type markers drive brain tumor growth.
Prestegarden L; Svendsen A; Wang J; Sleire L; Skaftnesmo KO; Bjerkvig R; Yan T; Askland L; Persson A; Sakariassen PØ; Enger PØ
Cancer Res; 2010 Jun; 70(11):4274-9. PubMed ID: 20460538
[TBL] [Abstract][Full Text] [Related]
15. Comparative analysis of DNA repair in stem and nonstem glioma cell cultures.
Ropolo M; Daga A; Griffero F; Foresta M; Casartelli G; Zunino A; Poggi A; Cappelli E; Zona G; Spaziante R; Corte G; Frosina G
Mol Cancer Res; 2009 Mar; 7(3):383-92. PubMed ID: 19276180
[TBL] [Abstract][Full Text] [Related]
16. The cancer stem cell marker CD133 has high prognostic impact but unknown functional relevance for the metastasis of human colon cancer.
Horst D; Scheel SK; Liebmann S; Neumann J; Maatz S; Kirchner T; Jung A
J Pathol; 2009 Dec; 219(4):427-34. PubMed ID: 19621338
[TBL] [Abstract][Full Text] [Related]
17. Expression of multidrug resistance genes in normal and cancer stem cells.
Shervington A; Lu C
Cancer Invest; 2008 Jun; 26(5):535-42. PubMed ID: 18568776
[TBL] [Abstract][Full Text] [Related]
18. CD133+ liver cancer stem cells from methionine adenosyl transferase 1A-deficient mice demonstrate resistance to transforming growth factor (TGF)-beta-induced apoptosis.
Ding W; Mouzaki M; You H; Laird JC; Mato J; Lu SC; Rountree CB
Hepatology; 2009 Apr; 49(4):1277-86. PubMed ID: 19115422
[TBL] [Abstract][Full Text] [Related]
19. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma.
Liu G; Yuan X; Zeng Z; Tunici P; Ng H; Abdulkadir IR; Lu L; Irvin D; Black KL; Yu JS
Mol Cancer; 2006 Dec; 5():67. PubMed ID: 17140455
[TBL] [Abstract][Full Text] [Related]
20. ERK and PI3K signaling cascades induce Nrf2 activation and regulate cell viability partly through Nrf2 in human glioblastoma cells.
Cong ZX; Wang HD; Wang JW; Zhou Y; Pan H; Zhang DD; Zhu L
Oncol Rep; 2013 Aug; 30(2):715-22. PubMed ID: 23708697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
